Abstract:Colorectal cancer (CRC) is a complex disease with diverse etiologies and clinical outcomes. Despite considerable progress in development of CRC therapeutics, challenges remain regarding the diagnosis and management of advanced stage metastatic CRC (mCRC). In particular, the five-year survival rate is very low since mCRC is currently rarely curable. Over the past decade, cancer treatment has significantly improved with the introduction of cancer immunotherapies, specifically immune checkpoint inhibitors. Therapies aimed at blocking immune checkpoints such as PD-1, PD-L1, and CTLA-4 target inhibitory pathways of the immune system, and thereby enhance anti-tumor immunity. These therapies thus have shown promising results in many clinical trials alone or in combination. The efficacy and safety of immunotherapy, either alone or in combination with CRC, have been investigated in several clinical trials. Clinical trials, including KEYNOTE-164 and CheckMate 142, have led to Food and Drug Administration approval of the PD-1 inhibitors pembrolizumab and nivolumab, respectively, for the treatment of patients with unresectable or metastatic microsatellite instability-high or deficient mismatch repair CRC. Unfortunately, these drugs benefit only a small percentage of patients, with the benefits of immunotherapy remaining elusive for the vast majority of CRC patients. To this end, primary and secondary resistance to immunotherapy remains a significant issue, and further research is necessary to optimize the use of immunotherapy in CRC and identify biomarkers to predict the response. This review provides a comprehensive overview of the clinical trials involving immune checkpoint inhibitors in CRC. The underlying rationale, challenges faced, and potential future steps to improve the prognosis and enhance the likelihood of successful trials in this field are discussed.

Immune Checkpoint Inhibitor Therapy in Colorectal Cancer—The Role of Cellular Pathology

Current Status and Future Perspective of Immune Checkpoint Inhibitors in Colorectal Cancer.

Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions

Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer

Immunogenic cell death in colorectal cancer: a review of mechanisms and clinical utility

Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy

Immunotherapy in colorectal cancer: rationale, challenges and potential

Tumor Immune Checkpoints and Their Associated Inhibitors

Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy

Immunotherapies catering to the unmet medical need of cold colorectal cancer

Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions

Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer

Exploring immunotherapy in colorectal cancer

Immune checkpoint inhibitors in colorectal cancer: limitation and challenges

Cancer Immunotherapy: The Checkpoint between Chronic Colitis and Colorectal Cancer

T-cell-based Immunotherapy in Colorectal Cancer

Immunotherapy for colorectal cancer:current status, challenges and solution

Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine

Strategy to Targeting the Immune Resistance and Novel Therapy in Colorectal Cancer

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Immune checkpoint inhibition in advanced colorectal cancer with inherited and acquired microsatellite instability: Current state and future directions